Member Info for Bobat1234

Excellent research. Very under valued.

Horrible spread but if it narrows we might see a lot more traders......

Mms not allowing buy quotes.

Buys coming in now. No placing required. Dyor

Last raised in December 2024 from rns.

Like renx most probably placing rns.

Sold. Moved profits into GENF.

Director bought in . Very cheap at the moment. Gla

Director also bought in.

Dr. Eric Leire, CEO of the Company, purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the open market.

Conclusion - Genflow Biosciences Share

The share price of Genflow Biosciences Plc Ord is expected to gradually increase between 2025 and 2030, bolstered by possible advancements in the study of anti-aging treatments. Although there are chances for significant profits, investing in biotechnology entails risks because of financial requirements, trial results, and regulatory barriers. Long-term investors with a high-risk appetite may find Genflow an intriguing addition to their portfolios.

Buys getting printed now.

Mms printing buys as sells.

Jonathan Mark Swann

8.4%

Holding rns printed now

https://www.lse.co.uk/rns/GENF/holdings-in-company-8u5vzr4fhdwsbxu.html

Rns now showing on advfn

Rns out on lse. Not on advfn not showing

19, September 2025

Genflow Biosciences Plc

Genflow Strengthens Global IP Portfolio with China Patent Examination Filing for SIRT6 Variants in NASH

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, today announces that it has filed a formal request for the examination of its patent application entitled SIRT6 Variants for NASH in China.

The application covers proprietary variants of the SIRT6 gene designed to address Non-Alcoholic Steatohepatitis (NASH), a severe progressive liver disease with limited treatment options. By pursuing examination in China, Genflow is reinforcing its global intellectual property portfolio and furthering its commitment to developing innovative therapies for patients worldwide.

Dr. Eric Leire, CEO of Genflow, commented: "The filing of this examination request in China represents another significant step in protecting our technology in one of the world's largest healthcare markets. We are committed to advancing our research into SIRT6-based therapies and believe that our approach holds strong potential to transform the treatment landscape for NASH."

Genflow Biosciences PLC, up 9.0% at 1.20 pence, 12-month range 0.55p-2.30p. The biotechnology firm, focused on therapies that target the ageing process, files a formal request for the examination of a patent application in China. The patent covers variants of the SIRT6 gene designed to address non-alcoholic steatohepatitis, a liver disease that has "limited treatment options".

----------

Bought in. Rns looks good. Gla

Welcome ladybay. You are most welcome here

Mms in bother. No shares left. Gla

Peeps have a look at omi. Going up. Fully funded. Placing done